References
1. Gilhus NE. Myasthenia Gravis. N Engl J Med 2016;375 :2570-81.
2. Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A,
Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M,
Palace J, Richman D, Verschuuren J. International Consensus Guidance for
Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96 :114-22.
3. Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico
C. Rituximab in AChR subtype of myasthenia gravis: systematic
review. J Neurol Neurosurg Psychiatry 2020; 91 :392-5.
4. Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F.
Comparison Between Rituximab Treatment for New-Onset Generalized
Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.JAMA Neurol 2020; 77 :974-81.
5. Leitner J, Grabmeier-Pfistershammer K, Steinberger P. Receptors and
ligands implicated in human T cell costimulatory processes.Immunol Lett 2010; 128 :89-97.
6. Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the
costimulatory molecule OX40 in T-cell-mediated immunity. Acta
Pharm Sin B 2020; 10 :414-33.
7. Edner NM, Carlesso G, Rush JS, Walker LSK. Targeting co-stimulatory
molecules in autoimmune disease. Nat Rev Drug Discov 2020;19 :860-83.
8. Webb GJ, Hirschfield GM, Lane PJ. OX40, OX40L and Autoimmunity: a
Comprehensive Review. Clin Rev Allergy Immunol 2016;50 :312-32.
9. Carboni S, Aboul-Enein F, Waltzinger C, Killeen N, Lassmann H,
Pena-Rossi C. CD134 plays a crucial role in the pathogenesis of EAE and
is upregulated in the CNS of patients with multiple sclerosis. J
Neuroimmunol 2003; 145 :1-11.
10. Jacquemin C, Augusto JF, Scherlinger M, Gensous N, Forcade E,
Douchet I, Levionnois E, Richez C, Lazaro E, Duffau P, Truchetet ME,
Seneschal J, Couzi L, Pellegrin JL, Viallard JF, Schaeverbeke T, Pascual
V, Contin-Bordes C, Blanco P. OX40L/OX40 axis impairs follicular and
natural Treg function in human SLE. JCI Insight 2018; 3 .
11. Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets
for the treatment of rheumatic diseases. Nat Rev Rheumatol 2017;13 :217-33.
12. An J, Ding S, Li S, Sun L, Chang X, Huang Z, Zhou B, Fang C, Liu C,
Zhang X. Enhancement of the Soluble Form of OX40 and OX40L Costimulatory
Molecules but Reduction of the Membrane Form in Type 1 Diabetes
(T1D). J Immunol Res 2019; 2019 :1780567.
13. Farres MN, Al-Zifzaf DS, Aly AA, Abd Raboh NM. OX40/OX40L in
systemic lupus erythematosus: association with disease activity and
lupus nephritis. Ann Saudi Med 2011; 31 :29-34.
14. Kshirsagar S, Binder E, Riedl M, Wechselberger G, Steichen E,
Edelbauer M. Enhanced activity of Akt in Teff cells from children with
lupus nephritis is associated with reduced induction of tumor necrosis
factor receptor-associated factor 6 and increased OX40
expression. Arthritis Rheum 2013; 65 :2996-3006.
15. Fu N, Xie F, Sun Z, Wang Q. The OX40/OX40L Axis Regulates T
Follicular Helper Cell Differentiation: Implications for Autoimmune
Diseases. Front Immunol 2021; 12 :670637.
16. Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC,
Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical
research standards. Task Force of the Medical Scientific Advisory Board
of the Myasthenia Gravis Foundation of America. Neurology 2000;55 :16-23.
17. Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with
antibodies to muscle-specific kinase. Autoimmun Rev 2013;12 :931-5.
18. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz
N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP,
Verschuuren J, Narayanaswami P. International consensus guidance for
management of myasthenia gravis: Executive summary. Neurology
2016; 87 :419-25.
19. Cui D, Lv Y, Yuan X, Ruan G, Zhang Y, Yan C, Xu D, Lv M, Mao Y, Cao
J, Jin J, Xie J. Increased Expressions of OX40 and OX40 Ligand in
Patients with Primary Immune Thrombocytopenia. J Immunol Res
2019; 2019 :6804806.
20. Jacquemin C, Schmitt N, Contin-Bordes C, Liu Y, Narayanan P,
Seneschal J, Maurouard T, Dougall D, Davizon ES, Dumortier H, Douchet I,
Raffray L, Richez C, Lazaro E, Duffau P, Truchetet ME, Khoryati L,
Mercie P, Couzi L, Merville P, Schaeverbeke T, Viallard JF, Pellegrin
JL, Moreau JF, Muller S, Zurawski S, Coffman RL, Pascual V, Ueno H,
Blanco P. OX40 Ligand Contributes to Human Lupus Pathogenesis by
Promoting T Follicular Helper Response. Immunity 2015;42 :1159-70.
21. Wang Q, Shi BM, Xie F, Fu ZY, Chen YJ, An JN, Ma Y, Liu CP, Zhang
XK, Zhang XG. Enhancement of CD4(+) T cell response and survival via
coexpressed OX40/OX40L in Graves’ disease. Mol Cell Endocrinol
2016; 430 :115-24.
22. Artinger K, Kirsch AH, Mooslechner AA, Cooper DJ, Aringer I,
Schuller M, Schabhuttl C, Klotzer KA, Schweighofer K, Eller P, Yagita H,
Illert AL, Rosenkranz AR, Lane PJ, Eller K. Blockade of tumor necrosis
factor superfamily members CD30 and OX40 abrogates disease activity in
murine immune-mediated glomerulonephritis. Kidney Int 2021;100 :336-48.
23. Patschan S, Dolff S, Kribben A, Durig J, Patschan D, Wilde B,
Specker C, Philipp T, Witzke O. CD134 expression on CD4+ T cells is
associated with nephritis and disease activity in patients with systemic
lupus erythematosus. Clin Exp Immunol 2006; 145 :235-42.
24. Xiaoyan Z, Pirskanen R, Malmstrom V, Lefvert AK. Expression of OX40
(CD134) on CD4+ T-cells from patients with myasthenia gravis.Clin Exp Immunol 2006; 143 :110-6.
25. Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M.
The costimulation-regulated duration of PKB activation controls T cell
longevity. Nat Immunol 2004; 5 :150-8.
26. Prell RA, Evans DE, Thalhofer C, Shi T, Funatake C, Weinberg AD.
OX40-mediated memory T cell generation is TNF receptor-associated factor
2 dependent. J Immunol 2003; 171 :5997-6005.
27. Vu MD, Clarkson MR, Yagita H, Turka LA, Sayegh MH, Li XC. Critical,
but conditional, role of OX40 in memory T cell-mediated
rejection. J Immunol 2006; 176 :1394-401.
28. Soroosh P, Ine S, Sugamura K, Ishii N. Differential requirements for
OX40 signals on generation of effector and central memory CD4+ T
cells. J Immunol 2007; 179 :5014-23.
29. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M.
The OX40 costimulatory receptor determines the development of CD4 memory
by regulating primary clonal expansion. J Immunol 2000;165 :3043-50.
30. Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L
to T-cell biology and immune disease. Immunol Rev 2009;229 :173-91.
31. Zhang G, Hou J, Shi J, Yu G, Lu B, Zhang X. Soluble CD276 (B7-H3) is
released from monocytes, dendritic cells and activated T cells and is
detectable in normal human serum. Immunology 2008;123 :538-46.
32. Hu X, Wu J, An J, Hu Y, Shen Y, Liu C, Zhang X. Development of a
novel monoclonal antibody to human inducible co-stimulator ligand
(ICOSL): Biological characteristics and application for enzyme-linked
immunosorbent assay. Int Immunopharmacol 2016; 36 :151-7.
33. Tanaka Y, Takahashi Y, Tanaka R, Miyagi T, Saito M, Fukushima T.
Association of high levels of plasma OX40 with acute adult T-cell
leukemia. Int J Hematol 2019; 109 :319-27.
34. Sawada R, Arai Y, Sagawa Y, Nagata Y, Nishimura T, Noguchi M, Amano
K, Arihiro S, Saruta M, Homma S. High blood levels of soluble OX40
(CD134), an immune costimulatory molecule, indicate reduced survival in
patients with advanced colorectal cancer. Oncol Rep 2019;42 :2057-64.
35. Weinberg AD, Wegmann KW, Funatake C, Whitham RH. Blocking
OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T
cell function and amelioration of experimental allergic
encephalomyelitis. J Immunol 1999; 162 :1818-26.
36. Higgins LM, McDonald SA, Whittle N, Crockett N, Shields JG,
MacDonald TT. Regulation of T cell activation in vitro and in vivo by
targeting the OX40-OX40 ligand interaction: amelioration of ongoing
inflammatory bowel disease with an OX40-IgG fusion protein, but not with
an OX40 ligand-IgG fusion protein. J Immunol 1999;162 :486-93.
37. Soroosh P, Ine S, Sugamura K, Ishii N. OX40-OX40 ligand interaction
through T cell-T cell contact contributes to CD4 T cell
longevity. J Immunol 2006; 176 :5975-87.
38. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes
Bcl-xL and Bcl-2 expression and is essential for long-term survival of
CD4 T cells. Immunity 2001; 15 :445-55.
39. Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H,
Lutsiak ME, Khawli L, Hu P, Epstein AL. Fc-mOX40L fusion protein
produces complete remission and enhanced survival in 2 murine tumor
models. J Immunother 2008; 31 :235-45.
40. Qin W, Hongya W, Yongjing C, Fang X, Yue M, Xuekun Z, Xiaozhong L,
Xueguang Z. Increased OX40 and soluble OX40 ligands in children with
Henoch-Schonlein purpura: association with renal involvement.Pediatr Allergy Immunol 2011; 22 :54-9.